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Background:We examined whether an increased risk of cancer incidence and death is associated with kidney
function and albuminuria and whether the risk is more readily identified when kidney function is estimated
using cystatin C.
Methods: Participants were from UK Biobank (recruitment spanning 20072010), excluding those with a
prior diagnosis of cancer. Estimated glomerular filtration rate (ml/min/1.73m2) was calculated using creati-
nine (eGFRcr), cystatin C (eGFRcys) and creatinine-cystatin C (eGFRcr-cys). Cox proportional hazards models
tested associations between eGFR, urinary albumin:creatinine ratio (uACR) and cancer incidence and death.
Findings: In 431,263 participants over median follow-up of 11.3 (IQR 10.612.0) years, there were 41,745
incident cancers and 11,764 cancer deaths. eGFRcys was most strongly associated with cancer incidence and
death (HR 1.04 (95% CI 1.031.04) and 1.06 (1.051.07) per 10 ml/min/1.73m2 decline, respectively). eGFRcr
was not associated with either outcome (incidence: HR 1.00 (1.001.01); death: HR 0.99 (0.981.01) per
10 ml/min/1.73m2 decline). Relative to eGFRcys>90 or uACR<3 mg/mmol, eGFRcys6089 (HR 1.04 (95% CI
1.021.07)), eGFRcys<60 (HR 1.19 (1.141.24)) and uACR3 mg/mmol (HR 1.09 (1.061.12)) were associ-
ated with higher risk of incident cancer. eGFRcys6089 (HR 1.15 (1.101.21)); eGFRcys<60 (HR 1.48
(1.381.59)) and uACR3 mg/mmol (HR 1.17 (1.111.24)) were associated with cancer death.
Interpretation: Excess risk of cancer incidence and cancer death is more readily captured in early chronic kid-
ney disease by eGFRcys than by current measures. The association between kidney function, uACR and cancer
death in particular is concerning and warrants further scrutiny.
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Cancer is more common in people with advanced chronic kidney
disease (CKD) and/or kidney failure requiring kidney replacement
therapy (KRT) [1]. It is unclear when higher cancer risk begins in rela-
tion to the CKD life course.
As kidney function, defined by estimated glomerular filtration rate
(eGFR), falls below 60 ml/min/1.73m2, there is a well described
increased risk of cardiovascular disease [2] but this is less clear for
cancer risk. Several studies have demonstrated a potential association
between markers of CKD (below eGFR 60 ml/min/1.73m2, alone or in
combination with albuminuria) with higher risk of incidence and
death from overall [36] and site-specific urinary [3,79], lung[3]and haematological [10] cancers. However, the data are inconsistent
[1,4,7,11], possibly as most studies have assessed associations with
eGFR calculated from serum creatinine [1,3,5,712], which has been
shown to have a U-shaped relationship with cancer risk [12]. Inde-
pendent of the effect of eGFR and diabetes, albuminuria has been
associated with higher risk of cancer overall [4,5,13], and particularly
site-specific lung [4,5,13,14] and urinary tract [4,14] cancers.
Compared with creatinine, cystatin C is not influenced by muscle
mass, age, ethnicity and gender and, combined in an equation with
creatinine, affords more accurate estimation of kidney function than
creatinine alone [15]. For cardiovascular disease, risk prediction in
CKD is enhanced when cystatin C is used to estimate kidney function
[2,16]. This has not previously been explored for cancer outcomes.
The UK Biobank has over 500,000 participants and nearly 5 mil-
lion participant-years of follow-up. Using UK Biobank, we tested the
hypothesis that CKD markers (eGFR and albuminuria) are associated
Research in context
Evidence before the study
Cancer is more common in people with kidney failure, espe-
cially in people requiring dialysis or a kidney transplant.
Although kidney failure is relatively uncommon, mild kidney
disease (estimated glomerular filtration rate 6089 ml/min/
1.73m2) may be present in one third of the population, is usu-
ally asymptomatic, is not routinely diagnosed and is monitored
infrequently. Using sensitive markers of kidney dysfunction
(cystatin C), mild kidney disease is associated with 2030%
increase in risk of cardiovascular disease and early death, and
this heightened risk is more pronounced in people with more
advanced kidney disease (estimated glomerular filtration rate
<60 ml/min/1.73m2). This may also be true for some forms of
cancer, as kidney disease, cardiovascular disease and cancer
share common risk factors. The presence of albuminuria (urine
albumin:creatinine ratio >3 mg/mmol) is abnormal, and has
been shown previously to be associated with higher risk of can-
cer incidence and cancer death for some cancer subtypes.
Added value of this study
Using a more sensitive and intuitively linear marker of kidney
disease (cystatin C), we show that even mild kidney disease is
associated with a 4% increased risk of developing cancer and a
15% risk in dying from cancer. In people with more advanced
kidney disease, there is a 19% increased risk in developing cancer
and a 48% increased risk in dying from cancer. This heightened
risk of developing and dying from cancer is not identified when
kidney function is estimated using serum creatinine, the marker
most commonly used to estimate kidney function. Albuminuria
is associated with 9% increased risk of developing cancer and
17% risk of dying from cancer, independently of the association
between estimated glomerular filtration rate and cancer risk.
Implications of the available evidence
Our results show that mild kidney disease is clinically impor-
tant in predicting cancer risk (and risk of cardiovascular disease
and early death) but identifying this excess risk requires mea-
surement of more sensitive markers of kidney dysfunction such
as cystatin C. Greater uptake of cystatin C testing is clinically
warranted for risk stratification of cancer, cardiovascular dis-
ease and early death. Though cystatin C testing is available in
most developed countries, it is more expensive than creatinine
in many laboratories; however, more widespread use could
drive down the costs of testing and aid further research into
identifying and addressing the factors responsible for worse
cancer outcomes in people with kidney disease.
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2 J.S. Lees et al. / EClinicalMedicine 00 (2021) 101030with increased risk of overall and site-specific cancer incidence, can-
cer death, and that these risks are independent of known risk factors
for cancer. Additionally, we hypothesised that kidney function esti-
mates incorporating cystatin C, compared with creatinine alone,
would be more strongly associated with cancer incidence and can-
cer-specific outcomes.
2. Methods
2.1. Participants and baseline data collection
Data were collected from 502,536 participants of the UK Biobank
from 2007 to 2010 across assessment centres in the UK as previously
described [17,18]. All participants provided written informed consentPlease cite this article as: J.S. Lees et al., Kidney function and cancer r
EClinicalMedicine (2021), https://doi.org/10.1016/j.eclinm.2021.101030for baseline phenotyping and follow-up (with data linkage to elec-
tronic health records) until death or withdrawal of consent. The UK
Biobank obtained ethical approval from the North West Multi-Centre
Research Ethics Committee (REC reference 11/NW/03/820). The study
was conducted under UK Biobank project code 7155 and reported
according to STROBE principles.
Participants with available biochemistry at baseline and who pro-
vided ongoing consent for follow-up were included. Participants
were excluded if they had a pre-existing diagnosis of cancer at the
first UK Biobank assessment or if they did not have baseline biochem-
istry measurements.
Biochemical sampling processes have been described and vali-
dated previously [1922]. In brief, serum and spot urine samples
were collected and analysed at a central laboratory. eGFR was calcu-
lated using Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equations using serum creatinine (eGFRcr), cystatin C
(eGFRcys) or a combination of creatinine and cystatin C (eGFRcr-cys)
[15]. CKD stage was categorised according to the Kidney Disease:
Improving Global Outcomes standard classification [23]: 90 (Refer-
ence: eGFR90), >6089 (eGFR6089), >3060, >1530-, 15 ml/
min/1.73m2. Participants with eGFR <60 ml/min/1.73m2 were com-
bined into one group for analysis (eGFR<60) due to small numbers
with eGFR <30 ml/min/1.73m2. Albuminuria was calculated as urine
albumin:creatinine ratio (uACR) and categorised as <3 mg/mmol
(normal) and 3 mg/mmol (abnormal) owing to small numbers of
participants with uACR >30 mg/mmol.
Age was calculated from dates of birth and baseline assessment.
Body mass index (BMI) was calculated from weight(kg)/height(m)2.
Ethnicity, smoking and alcohol history were self-reported. Townsend
deprivation index [24] was calculated from the residential postcode.
Follow-up was recorded from first UK Biobank assessment date
until date of the relevant outcomes. The end of follow-up was defined
as the sooner of date of death, first diagnosis of cancer or the end of
data collection (1st June 2020 for death (all centres), 1st June 2020
for hospital admissions in England; 31st March 2017 for hospital
admissions in Scotland andWales).
2.2. Outcomes of interest
(i) Cancer incidence: via linkage to national cancer registries, rele-
vant cancer diagnoses were obtained using current ICD10 code
classifications and grouped as follows: overall cancer (C00-C97,
excluding non-melanoma skin cancer (D44)), digestive system
(oesophagus, stomach, small intestine, colon, rectosigmoid, rec-
tum and anal: C1521), head and neck cancers (lip, tongue, gum,
mouth, palate, parotid, salivary glands, tonsil, oropharynx, naso-
pharynx, sinus, hypopharynx, other oral; C0014), respiratory
system (trachea, bronchus and lung: C3334), abdominal solid
organs (liver, gallbladder, biliary tract, pancreas, other digestive:
C2225), haematological cancers (lymphoma, leukaemia, multi-
ple myeloma, immunoproliferative diseases and other malignant
haematological conditions (C8196), renal tract cancers (kidney,
renal pelvis, ureter, bladder: C6467), female cancers (breast,
vulva, vagina, cervix, uterus, ovary: C5056), male cancers (penis,
prostate, testis: C6062) and malignant melanoma (C43).
(ii) Cancer death: cause and date of death were obtained from death
certificates (National Health Service Information Centre for Eng-
land andWales or the NHS Central Register for Scotland).
2.3. Statistical analysis
For all analyses, results were obtained for eGFR categories using
eGFRcr, eGFRcys, eGFRcr-cys. Distribution of baseline risk factors and
missing data were displayed overall and by eGFR categories. Continu-
ous variables were displayed as mean (standard deviation; SD) orisk: An analysis using creatinine and cystatin C in a cohort study,
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was tested by visual inspection of histograms and quantile-quantile
plots for the full cohort and across eGFR categories. Categorical risk
factors were displayed as number (%). Tests for trends across catego-
ries were assessed by ANOVA, chi-squared tests or Wilcoxon rank-
sum tests as appropriate.
Missing data were multiply imputed by chained equations, using
the average of five separately imputed datasets, assuming the data
were missing at random and that the proportion of missing data was
<10%.
Cancer event rates were described in the whole cohort per 100,000
participants and per 100,000 person-years. Furthermore, cancer inci-
dence by cancer subtype was also described using the same approach
per 100,000 participants and per 100,000 person-years.
To assess the relationship between each eGFR measure and cancer
incidence and cancer death (overall), penalised splines of eGFR
against hazard ratios of each outcome were plotted, after adjustment
for age, sex, smoking and alcohol history, BMI, ethnicity, deprivation
index, C-reactive protein, uACR, systolic and diastolic blood pressure,
total and low-density lipoprotein (LDL) cholesterol, use of antihyper-
tensive medications, use of cholesterol-lowering medications, base-
line hypertension, diabetes and cardiovascular disease. eGFR 90 ml/
min/1.73m2 was considered the reference value for all outcomes.
Cox proportional hazards models were constructed to assess the
association between eGFR measures and risk of cancer incidence
(overall and by subtype) and cancer death (overall and by subtype)
by 10 ml/min/1.73m2 reduction in eGFR, by one standard deviation
reduction in eGFR, and across eGFR categories (eGFR90,
eGFR6089, eGFR<60). Similar models were conducted to assess the
effect of uACR on cancer incidence and death (overall and by subtype)
in those with uACR <3 versus 3 mg/mmol. Proportional hazard
assumptions were checked by plotting Schoenfeld residuals. Cox
models were adjusted for known risk factors for cancer development
as above. Models to assess the impact of uACR category were
adjusted for eGFRcys. Evidence of multiplicative interaction effects
were sought between age, sex, eGFR, uACR and type 2 diabetes for all
outcomes using all eGFR measures. To attenuate the possibility of any
observed associations between eGFR and cancer outcomes being
linked to reverse causality, we conducted exploratory analyses for
cancer incidence and cancer death overall: (i) excluding participants
who developed multiple myeloma and renal tract cancers; (ii) 1-year
landmark analysis, excluding participants who developed cancer or
died within 1 year of enrolment. All survival models were censored
for the competing risk of non-cancer death.
Model fit of Cox proportional hazards models to predict cancer
incidence and death (overall and by subtype) was assessed by C-sta-
tistics with the addition of each eGFR measure as above, Akaike and
Bayesian Information Criteria (AIC and BIC respectively; significance
testing by log-likelihood ratios).
The rate advancement period (RAP): the time by which the risk is
advanced compared to 1 year of ageing) was estimated from the
regression coefficients (b) in fully-adjusted Cox proportional hazards
models using methods described previously [25]: RAP = bE/bA, where
bE represents the adjusted coefficient of the exposure variable, and
bA represents the regression coefficient for age. Confidence intervals
were estimated as follows [25]: bE/bA § 1.96 xvar(bE/bA). For RAP
analyses, BMI and deprivation index were assessed according to the
impact of a 5-unit increment.
Analyses were conducted using tidyverse, finalfit, ggplot2, Hmisc,
nephro, survival, survminer and tableone packages for R statistical soft-
ware (version 4.0.3) [26].
3. Role of funding
J.S.L. is funded by a Chief Scientist Office (Scotland) Postdoctoral
Lectureship Scheme (PCL/20/10). S.P.-S. receive financial supportPlease cite this article as: J.S. Lees et al., Kidney function and cancer r
EClinicalMedicine (2021), https://doi.org/10.1016/j.eclinm.2021.101030from the Chilean Government for doing their PhD (ANID-Becas Chile).
M.K.S. is funded by a Medical Research Council Clinical Research
Training Fellowship (MR/V001671/1). B.D.J.’s time was partly funded
by Dawkins and Strutt research grant from the British Medical Asso-
ciation. N.S. is supported by a British Heart Foundation Centre
Research Excellence Award (RE/18/6/34217).
4. Results
There were 502,493 participants available in the full dataset:
33,484 had missing biochemical data and 37,746 had a diagnosis of
cancer at baseline: 431,263 participants were included in the analy-
ses. Over median follow-up of 11.3 (IQR 10.612.0) years, there were
41,745 new diagnoses of cancer, 23,525 deaths from any-cause of
which 11,674 were cancer deaths.
4.1. Distribution of baseline risk factors according to eGFR categories
Baseline data by CKD stage can be found in Table 1 (eGFRcys),
Supplementary Data Tables 1 (eGFRcr) and 2 (eGFRcr-cys). Overall,
53.4% were female, median age overall was 57.0 (IQR 50.063.0)
years and 94.2% were of White ethnicity (2.0% South Asian and 1.6%
Black). With declining eGFR, cardiometabolic risk factors tended to
increase: compared to the reference group, participants with CKD
G35 were older (median age 64 (IQR 6167) versus 52 (IQR 4659)
years, p<0.001), with higher BMI (29.9 (IQR 26.634.1) versus 25.7
(IQR 23.4- 28.5) kg/m2, p<0.001) and systolic blood pressure (142
(SD 20) versus 135 (SD 18) mmHg, p<0.001). Participants with
eGFRcys<60 had a greater burden of cardiometabolic comorbidity at
baseline compared to the reference group (hypertension 58.1 versus
18.3%, p<0.001; type 2 diabetes 14.9 versus 3.2%, p<0.001; cardiovas-
cular disease 20.6 versus 3.6%, p<0.001).
4.2. Cancer event rates by eGFR category
Cancer event rates and incidence per 100,000 participants and per
100,000 person-years are displayed overall, by cancer subtype, and
by eGFR categories in Supplementary Tables 3 (eGFRcys), 4 (eGFRcr)
and 5 (eGFRcr-cys). Across all three measures, the rate of cancer inci-
dence-overall and across cancer subtypes-increased with reduction
in eGFR. This was more pronounced for eGFRcys and eGFRcr-cys.
4.3. Survival analysis
Risk of cancer incidence and cancer death are displayed graphi-
cally across the spectrum of eGFRcr, eGFRcys and eGFRcr-cys (Fig. 1).
The relationship between eGFR and both cancer outcomes were
largely linear and negative below ~90 ml/min/1.73m2 for eGFRcys
and eGFRcr-cys, and below ~75 ml/min/1.73m2 for eGFRcr, suggest-
ing that eGFRcys and eGFRcr-cys can detect heightened risk of cancer
at an earlier stage. However, there was a J-shaped relationship for
eGFRcr and eGFRcr-cys, with elevated risk of cancer incidence and
death >90 ml/min/1.73m2. This was more pronounced for eGFRcr.
For each reduction in eGFR by 10 ml/min/1.73m2 or by one standard
deviation, there was a stronger association between cancer incidence
and death overall with eGFRcys than with eGFRcr or eGFRcr-cys
(Table 2). Increasing uACR was positively associated with risk of both
cancer outcomes, plateauing at uACR ~90 mg/mmol for cancer inci-
dence and ~80 mg/mmol for cancer death (Fig. 1).
4.3.1. Cancer incidence-overall
On multivariable analysis, increasing age, male sex, higher BMI, C-
reactive protein, smoking and alcohol history, ethnicity, increasing
deprivation, total and LDL cholesterol, cholesterol-lowering and anti-
hypertensive medications and history of type 2 diabetes were allisk: An analysis using creatinine and cystatin C in a cohort study,
Table 1
Baseline characteristics across eGFRcys categories.







N= 431,263 212,516 200,067 18,680
Age (years): Median [IQR] 57.00 [50.00, 63.00] 52.00 [46.00, 59.00] 61.00 [55.00, 65.00] 64.00 [61.00, 67.00] <0.001
Sex: N(%) Female 230,374 (53.4) 118,681 (55.8) 101,900 (50.9) 9793 (52.4) <0.001
Male 200,889 (46.6) 93,835 (44.2) 98,167 (49.1) 8887 (47.6)
Deprivation index*: Median [IQR] 2.15 [3.65, 0.51] 2.20 [3.69, 0.38] 2.16 [3.64, 0.53] 1.32 [3.22, 1.89] <0.001
Missing: N(%) 531 (0.12) 268 (0.13) 247 (0.12) 16 (0.09)
Body mass index: Median [IQR] 26.74 [24.14, 29.88] 25.74 [23.38, 28.52] 27.64 [24.99, 30.86] 29.90 [26.57, 34.05] <0.001
Missing: N(%) 1450 (0.34) 584 (0.27) 699 (0.35) 167 (0.89)
Ethnicity: N(%) White 406,242 (94.2) 198,171 (93.2) 190,579 (95.3) 17,492 (93.6) <0.001
Black 6929 (1.6) 4635 (2.2) 2085 (1.0) 209 (1.1)
Chinese 1375 (0.3) 1060 (0.5) 303 (0.2) 12 (0.1)
Mixed 2587 (0.6) 1672 (0.8) 855 (0.4) 60 (0.3)
South Asian 8703 (2.0) 3876 (1.8) 4130 (2.1) 697 (3.7)
Any other 3951 (0.9) 2415 (1.1) 1398 (0.7) 138 (0.7)
Missing 1476 (0.3) 687 (0.3) 717 (0.4) 72 (0.4)
Smoking status: N(%) Never 236,745 (55.1) 125,099 (59.0) 103,451 (51.9) 8195 (44.2) <0.001
Previous 147,456 (34.3) 68,646 (32.4) 71,548 (35.9) 7262 (39.1)
Current 45,477 (10.6) 18,181 (8.6) 24,200 (12.1) 3096 (16.7)
Missing: N(%) 0 (0) 0 (0) 0 (0) 0 (0)
Alcohol intake (units/week) 16.47 (19.00) 17.49 (18.98) 15.82 (19.04) 11.72 (17.77) <0.001
Missing: N(%) 37,455 (8.7) 17,332 (8.2) 18,265 (9.1) 1858 (9.9)
Systolic blood pressure (mmHg) 137.68 (18.60) 134.60 (18.07) 140.56 (18.52) 141.85 (19.62) <0.001
Missing: N(%) 24,394 (5.7) 11,905 (5.6) 18,265 (9.1) 1120 (6.0)
Diastolic blood pressure (mmHg) 82.22 (10.12) 81.35 (10.05) 83.16 (10.07) 81.93 (10.60) <0.001
Missing: N(%) 37,269 (8.6) 18,047 (8.5) 17,424 (8.7) 1798 (9.6)
Medications for cholesterol: N(%) Yes 74,026 (17.2) 23,738 (11.2) 42,544 (21.3) 7744 (41.5) <0.001
Missing: N(%) 0 (0) 0 (0) 0 (0) 0 (0)
Medications for
hypertension: N(%)
Yes 88,399 (20.5) 26,749 (12.6) 51,268 (25.6) 10,382 (55.6) <0.001
Missing: N(%) 0 (0) 0 (0) 0 (0) 0 (0)
Total cholesterol (mmol/l) 5.69 (1.14) 5.67 (1.08) 5.74 (1.18) 5.32 (1.28) <0.001
Missing: N(%) 131 (0.03) 67 (0.03) 57 (0.03) 7 (0.04)
LDL cholesterol (mmol/l) 3.55 (0.87) 3.52 (0.83) 3.61 (0.89) 3.33 (0.96) <0.001
Missing: N(%) 844 (0.2) 446 (0.21) 359 (0.18) 39 (0.21)
uACR (mg/mmol): Median [IQR] 1.09 [0.69, 1.85] 1.14 [0.70, 1.92] 1.05 [0.67, 1.75] 1.22 [0.74, 2.36] <0.001
Missing: N(%) 12,214 (2.8) 5515 (2.6) 5867 (2.9) 832 (4.5)
uACR category: N(%) <3 mg/mmol 377,618 (90.1) 186,068 (89.9) 177,151 (91.2) 14,399 (80.7) <0.001
>=3 mg/mmol 41,431 (9.9) 20,933 (10.1) 17,049 (8.8) 3449 (19.3)
C-reactive protein (ng/ml): Median [IQR] 1.31 [0.65, 2.73] 0.99 [0.51, 2.04] 1.63 [0.84, 3.24] 2.81 [1.43, 5.64] <0.001
Missing: N(%) 687 (0.16) 334 (0.16) 324 (0.16) 29 (0.16)
Type 1 diabetes: N(%) Yes 1388 (0.3) 671 (0.3) 520 (0.3) 197 (1.1) <0.001
Missing 0 (0) 0 (0) 0 (0) 0 (0)
Type 2 diabetes: N(%) Yes 19,900 (4.6) 6848 (3.2) 10,269 (5.1) 2783 (14.9) <0.001
Missing 0 (0) 0 (0) 0 (0) 0 (0)
Hypertension: N(%) Yes 112,955 (26.2) 38,938 (18.3) 63,173 (31.6) 10,844 (58.1) <0.001
Missing 0 (0) 0 (0) 0 (0) 0 (0)
Cardiovascular disease: N(%) Yes 28,239 (6.5) 7631 (3.6) 16,756 (8.4) 3852 (20.6) <0.001
Missing 0 (0) 0 (0) 0 (0) 0 (0)
* Townsend deprivation index: each participant was assigned a numerical score corresponding to their postcode (range 6.26  11.00) with higher number rep-
resenting greater deprivation. Data are presented as mean (standard deviation) unless otherwise indicated.
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(p<0.05 for all).
After multivariable adjustment, there was a small but detectable
increase in cancer incidence in people with eGFRcys6089 (HR 1.04
(95% CI 1.021.07), p<0.001) and a higher increase in risk in people
with eGFRcys<60 (HR 1.19 (1.141.24), p<0.001). This increase in
risk was not detected by eGFRcr. uACR3 mg/mmol was indepen-
dently associated with increased risk of cancer incidence (HR 1.09
(1.061.12), p<0.001).4.3.2. Cancer death-overall
Increasing age, male sex, higher BMI, C-reactive protein, smoking
and alcohol history, ethnicity, increasing deprivation, uACR, C-reac-
tive protein, systolic blood pressure, medications for cholesterol and
blood pressure, total and LDL cholesterol and history of type 2 diabe-
tes and cardiovascular disease were all independently associated
with higher risk of cancer death (p<0.05 for all).Please cite this article as: J.S. Lees et al., Kidney function and cancer r
EClinicalMedicine (2021), https://doi.org/10.1016/j.eclinm.2021.101030After adjustment, there was a moderate increase in cancer death
in people with eGFRcys6089 (HR 1.15 (1.101.21), p<0.001) and a
more pronounced increase in risk in people with eGFRcys<60 (HR
1.48 (1.381.59), p<0.001). This increase in risk was not detected by
eGFRcr. uACR3 mg/mmol was independently associated with
increased risk of cancer death (HR 1.17 (1.111.24), p<0.001).
There was a multiplicative interaction detected between age and
sex for all eGFR measures with both cancer incidence and cancer
death (p<0.001), with older men demonstrating highest increase in
cancer risk. Statistical interactions between eGFR and uACR, type 2
diabetes, age and sex were variable according to the eGFR measure
and cancer outcome (Supplementary Table 6). Exploratory analyses
(Tables 3 and 4) suggest that eGFRcys<60 may be more strongly
associated with cancer outcomes in those without type 2 diabetes
(incidence: HR 1.20 (1.141.25) versus 1.14 (1.011.30); death: 1.53
(1.411.65) versus 1.28 (1.041.57)). uACR 3 mg/mmol may be
more strongly associated with cancer death in younger compared
with older participants (Table 4). Similar associations between eGFRisk: An analysis using creatinine and cystatin C in a cohort study,
Fig. 1. Adjusted penalised splines of risk of cancer incidence and cancer death across the spectrum of eGFRcr, eGFRcys, eGFRcr-cys and uACR. Penalised splines of hazard ratios (95% confi-
dence intervals) of each outcome were plotted for all eGFR measures and for uACR, after adjustment for known risk factors for cancer development: age, sex, smoking and alcohol
history, BMI, ethnicity, deprivation index, C-reactive protein, uACR (for all eGFR splines), eGFRcys (for uACR splines only), systolic and diastolic blood pressure, total and LDL choles-
terol, use of antihypertensive medication, use of cholesterol-lowering medication, baseline diabetes, hypertension and cardiovascular disease. eGFR 90 ml/min/1.73m2 was consid-
ered the reference value for all outcomes. P nonlinear: likelihood-ratio test for addition of eGFR as a continuous variable to adjusted Cox proportional hazards model adjusted for
other variables as above. P Overall: likelihood-ratio test for addition of eGFR as a spline term to Cox proportional hazards model adjusted for other variables as above.
Table 2
Hazard ratios for cancer incidence and cancer death for each eGFR measure and displayed per 10 ml/min/1.73m2 and
per one standard deviation reduction in eGFR. Hazard ratios were estimated from Cox proportional hazards models
adjusted for age, sex, smoking and alcohol history, BMI, ethnicity, deprivation index, C-reactive protein, uACR, systolic
and diastolic blood pressure, total and LDL cholesterol, use of antihypertensive medication, use of cholesterol-lowering
medication, baseline diabetes, hypertension and cardiovascular disease.
Per 10 ml/min/1.73m2 reduction in eGFR Per 1 SD reduction in eGFR
Adjusted HR (95% CI, p value) 1 SD (ml/min/1.73m2) Adjusted HR (95% CI, p value)
Cancer incidence (41,745 incident cancers/431,263 participants)
eGFRcr 1.00 (1.001.01, p = 0.303) 13.4 1.01 (0.991.02, p = 0.303)
eGFRcys 1.04 (1.031.04, p<0.001) 16.1 1.06 (1.051.07, p<0.001)
eGFRcr-cys 1.03 (1.021.03, p<0.001) 14.2 1.04 (1.031.05, p<0.001)
Cancer death (11,764 cancer deaths/431,263 participants)
eGFRcr 0.99 (0.981.01, p = 0.288) 13.4 0.99 (0.971.01, p = 0.288)
eGFRcys 1.10 (1.081.11, p<0.001) 16.1 1.16 (1.131.18, p<0.001)
eGFRcr-cys 1.06 (1.051.08, p<0.001) 14.2 1.09 (1.071.11, p<0.001)
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and women (Table 4). eGFRcys<60 may be associated with higher
incidence in cancer death in younger compared with older women
(HR 1.49 (1.271.75) versus HR 1.34 (1.121.60); Table 4).
The addition of eGFRcys and eGFRcr-cys, but not eGFRcr,
improved model fit for cancer incidence overall (Supplementary
Tables 7 and 8). The greatest improvement was observed with
eGFRcys.
4.3.3. Cancer incidence-subtypes
eGFRcys6089 was associated with increased risk of haematological
malignancies (HR 1.24 (1.141.33): 25.1% multiple myeloma) and can-
cers of the abdominal solid organs (HR 1.12 (1.011.25)), renal (HR 1.11
(1.011.21)) and respiratory tracts (HR 1.11 (1.031.20)), and this risk
was augmented for each of these cancer subtypes when eGFRcys<60
(Fig. 2). eGFRcr6089 was not associated with increased risk of any of
these cancer subtypes but eGFRcr<60 was associated with increased
risk of haematological (HR 1.19 (1.001.41)) and renal (HR 1.30
(1.101.53)) cancers. uACR 3 mg/mmol was convincingly associated
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(HR 1.40 (1.231.58)), renal (HR 1.40 (1.271.54)) and respiratory (HR
1.20 (1.091.32)) cancers, with weaker associations with digestive and
head and neck cancers (Fig. 2).
The addition of eGFRcys improved model fit for cancer incidence
in the respiratory and renal tracts, abdominal solid organs and hae-
matological cancers but not head and neck, digestive tract, male/
female-specific cancers or melanoma (Supplementary Table 7).
4.3.4. Cancer death-subtypes
eGFRcys6089 was associated with increased risk of death from
haematological malignancies (HR 1.40 (1.201.64): 20.8% deaths
from multiple myeloma), digestive (HR 1.22 (1.101.35) and respira-
tory cancers (HR 1.15 (1.031.27)) with stronger associations
detected for eGFRcys<60 (Fig. 3). eGFRcys<60 was further associated
with risk of death from abdominal solid organ (HR 1.36 (1.111.66)),
head and neck (HR 2.50 (1.404.47)), male-specific (HR 1.46
(1.081.96)) and renal (HR 1.77 (1.342.35)) cancers. eGFRcr<60
was associated with increased risk of death from renal tract cancersisk: An analysis using creatinine and cystatin C in a cohort study,
Table 3
Hazard ratios and 95% confidence intervals for cancer incidence: model adjusted for age, sex, smoking and alcohol history, BMI, ethnicity, deprivation index, C-reactive protein,
uACR (for eGFR categories), eGFRcys (for uACR categories), systolic and diastolic blood pressure, total and LDL cholesterol, use of antihypertensive medication, use of cholesterol-
lowering medication, baseline diabetes, hypertension and cardiovascular disease.
REF eGFR 90 ml/min/1.73m2 eGFR 6089 ml/min/1.73m2 eGFR <60 ml/min/1.73m2 REF uACR <3 mg/mmol uACR normal 3 mg/mmol
Reference HR Adjusted HR (95% CI, p value) Adjusted HR (95% CI, p value) Reference HR Adjusted HR (95% CI, p value)
Older Men  65 years (7598 incident cancers/39,345 participants)
eGFRcr 1 1.03 (0.981.08, p = 0.261) 1.08 (0.971.20, p = 0.153)
eGFRcys 1 1.06 (1.001.13, p = 0.043) 1.24 (1.141.35, p<0.001) 1 1.13 (1.051.22, p = 0.001)
eGFRcr-cys 1 1.04 (0.981.10, p = 0.212) 1.18 (1.071.31, p = 0.001)
Younger Men < 65 years (14,381 incident cancers/161,544 participants)
eGFRcr 1 0.98 (0.951.01, p = 0.245) 1.09 (0.961.23, p = 0.174)
eGFRcys 1 1.06 (1.021.09, p = 0.003) 1.25 (1.151.36, p<0.001) 1 1.13 (1.061.20, p<0.001)
eGFRcr-cys 1 1.04 (1.001.08, p = 0.028) 1.30 (1.161.45, p<0.001)
Older Women  65 years (4989 incident cancers/38,978 participants)
eGFRcr 1 1.01 (0.951.07, p = 0.783) 1.02 (0.901.16, p = 0.752)
eGFRcys 1 1.09 (1.011.18, p = 0.021) 1.19 (1.071.32, p = 0.002) 1 1.08 (1.001.17, p = 0.066)
eGFRcr-cys 1 1.09 (1.021.17, p = 0.012) 1.14 (1.011.29, p = 0.039)
Younger Women < 65 years (14,777 incident cancers/191,396 participants)
eGFRcr 1 0.99 (0.961.03, p = 0.629) 1.06 (0.941.20, p = 0.321)
eGFRcys 1 1.02 (0.981.06, p = 0.254) 1.23 (1.131.35, p<0.001) 1 1.09 (1.041.14, p<0.001)
eGFRcr-cys 1 1.03 (1.001.07, p = 0.063) 1.17 (1.041.31, p = 0.009)
Type 2 diabetes (2748 cases/19,901 participants)
eGFRcr 1 0.97 (0.891.05, p = 0.418) 1.04 (0.891.21, p = 0.611)
eGFRcys 1 1.07 (0.971.18, p = 0.159) 1.14 (1.011.30, p = 0.041) 1 1.11 (1.011.22, p = 0.030)
eGFRcr-cys 1 1.03 (0.941.12, p = 0.525) 1.14 (0.991.31, p = 0.069)
No type 2 diabetes (38,991 cases/411,309 participants)
eGFRcr 1 1.00 (0.981.02, p = 0.899) 1.03 (0.971.10, p = 0.352)
eGFRcys 1 1.04 (1.021.06, p = 0.001) 1.20 (1.141.25, p<0.001) 1 1.09 (1.051.12, p<0.001)
eGFRcr-cys 1 1.04 (1.021.07, p<0.001) 1.16 (1.091.23, p<0.001)
Table 4
Hazard ratios and 95% confidence intervals for cancer death: model adjusted for age, sex, smoking and alcohol history, BMI, ethnicity, deprivation index, C-reactive protein, uACR
(for eGFR categories), eGFR (for uACR categories), systolic and diastolic blood pressure, total and LDL cholesterol, use of antihypertensive medication, use of cholesterol-lowering
medication, baseline diabetes, hypertension and cardiovascular disease.
REF eGFR 90 ml/min/1.73m2 eGFR 6089 ml/min/1.73m2 eGFR <60 ml/min/1.73m2 REF uACR <3 mg/mmol uACR normal 3 mg/mmol
Reference HR Adjusted HR (95% CI, p value) Adjusted HR (95% CI, p value) Reference HR Adjusted HR (95% CI, p value)
Older Men  65 years (2759 cancer deaths/39,345 participants)
eGFRcr 1 1.00 (0.921.09, p = 0.953) 1.20 (1.021.41, p = 0.027)
eGFRcys 1 1.13 (1.011.25, p = 0.026) 1.53 (1.331.76, p<0.001) 1 1.14 (1.011.28, p = 0.029)
eGFRcr-cys 1 1.08 (0.981.19, p = 0.103) 1.39 (1.191.63, p<0.001)
Younger Men < 65 years (3966 cancer deaths/161,544 participants)
eGFRcr 1 0.95 (0.891.01, p = 0.115) 1.11 (0.901.37, p = 0.328)
eGFRcys 1 1.19 (1.111.28, p<0.001) 1.54 (1.341.77, p<0.001) 1 1.26 (1.141.40, p<0.001)
eGFRcr-cys 1 1.12 (1.051.20, p = 0.001) 1.49 (1.231.79, p<0.001)
Older Women  65 years (1717 cancer deaths/38,978 participants)
eGFRcr 1 0.97 (0.871.07, p = 0.505) 1.03 (0.841.27, p = 0.772)
eGFRcys 1 1.11 (0.971.27, p = 0.123) 1.34 (1.121.60, p = 0.001) 1 1.13 (0.991.28, p = 0.080)
eGFRcr-cys 1 1.10 (0.971.24, p = 0.137) 1.22 (1.001.50, p = 0.054)
Younger Women < 65 years (3322 cancer deaths/191,396 participants)
eGFRcr 1 0.94 (0.881.02, p = 0.124) 1.05 (0.831.32, p = 0.677)
eGFRcys 1 1.13 (1.051.23, p = 0.002) 1.49 (1.271.75, p<0.001) 1 1.21 (1.101.33, p<0.001)
eGFRcr-cys 1 1.10 (1.021.19, p = 0.010) 1.28 (1.031.59, p = 0.023)
Type 2 diabetes (1073 cancer deaths/19,901 participants)
eGFRcr 1 0.89 (0.781.02, p = 0.091) 1.09 (0.861.37, p = 0.477)
eGFRcys 1 1.16 (0.991.35, p = 0.065) 1.28 (1.041.57, p = 0.020) 1 1.18 (1.021.37, p = 0.027)
eGFRcr-cys 1 1.18 (1.021.36, p = 0.026) 1.29 (1.031.61, p = 0.027)
No type 2 diabetes (10,689 cancer deaths/411,309 participants)
eGFRcr 1 0.97 (0.931.01, p = 0.153) 1.09 (0.981.21, p = 0.131)
eGFRcys 1 1.15 (1.101.21, p<0.001) 1.53 (1.411.65, p<0.001) 1 1.17 (1.111.24, p<0.001)
eGFRcr-cys 1 1.10 (1.051.15, p<0.001) 1.37 (1.241.51, p<0.001)
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with a reduced risk of death from abdominal solid organ and male-
specific cancers (Fig. 3). uACR 3 mg/mmol was associated with
increased risk of death from abdominal (HR 1.22 (1.061.41)), diges-
tive (HR 1.14 (1.011.30), renal (HR 1.73 (1.422.11) and respiratory
(HR 1.19 (1.06  1.34) cancers (Fig. 3).
The addition of eGFRcys improved model fit for death from diges-
tive, respiratory, abdominal, head and neck, haematological and renal
tract cancers (Supplementary Table 8).Please cite this article as: J.S. Lees et al., Kidney function and cancer r
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tract cancers
After exclusion of 4524 participants diagnosed with multiple
myeloma or renal tract cancers, eGFRcys remained associated with
increased risk of cancer incidence (eGFRcys 6089: HR 1.03
(1.011.05), p = 0.016); eGFRcys<60: HR 1.15 (1.101.20),
p<0.001) and cancer death (eGFRcys6089: HR 1.14 (1.091.20),
p<0.001); eGFRcys<60 HR 1.44 (1.341.56), p<0.001; Supplemen-
tary Table 9).isk: An analysis using creatinine and cystatin C in a cohort study,
Fig. 2. Forest plots for cancer incidence by cancer subtype according to eGFR and uACR categories. Results are presented as the hazard ratio and 95% confidence intervals (adjusted for
age, sex, smoking and alcohol history, BMI, ethnicity, deprivation index, C-reactive protein, uACR (for eGFR categories), eGFRcys (for uACR categories), systolic and diastolic blood
pressure, total and LDL cholesterol, use of antihypertensive medication, use of cholesterol-lowering medication, baseline diabetes, hypertension and cardiovascular disease). Results
are stratified by eGFRcr, eGFRcys and eGFRcr-cys categories and compared to reference group with eGFR >90 ml/min/1.73m2. For uACR category, uACR >= 3 mg/mmol is presented
compared to the reference group with uACR <3 mg/mmol, after adjustment for eGFRcys and other variables as above.
Fig. 3. Forest plots for cancer death by cancer subtype according to eGFR and uACR categories. Results are presented as the hazard ratio and 95% confidence intervals (adjusted for age,
sex, smoking and alcohol history, BMI, ethnicity, deprivation index, C-reactive protein, uACR (for eGFR categories), eGFRcys (for uACR category), systolic and diastolic blood pres-
sure, total and LDL cholesterol, use of antihypertensive medication, use of cholesterol-lowering medication, baseline diabetes, hypertension and cardiovascular disease). Results are
stratified by eGFRcr, eGFRcys and eGFRcr-cys categories and compared to reference group with eGFR >90 ml/min/1.73m2. For uACR category, uACR >= 3 mg/mmol is presented
compared to the reference group with uACR <3 mg/mmol, after adjustment for eGFRcys and other variables as above.
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After exclusion of 6386 participants who were diagnosed with
cancer or died within one year of enrolment, eGFRcys remained asso-
ciated with increased risk of cancer incidence (eGFRcys 6089: HR
1.04 (1.021.07), p<0.001); eGFRcys<60: HR 1.20 (1.151.25),
p<0.001) and cancer death (eGFRcys6089: HR 1.16 (1.111.21),
Please cite this article as: J.S. Lees et al., Kidney function and cancer r
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tary Table 10).
4.3.7. Rate advancement periods
After multivariable adjustment, eGFRcys<60 was associated with
a RAP of 2.8 (2.5  8.1) years, i.e., an advance in risk of cancer
isk: An analysis using creatinine and cystatin C in a cohort study,
Table 5
Rate advancement periods with 95% confidence intervals for overall cancer incidence and cancer death. The rate advancement period
(RAP): the time by which the risk is advanced compared to 1 year of ageing) was estimated from the regression coefficients (b) in Cox pro-
portional hazards models. All Cox proportional hazards models were adjusted for age, sex, smoking and alcohol history, BMI, ethnicity,
deprivation index, C-reactive protein, uACR, eGFRcys, systolic and diastolic blood pressure, total and LDL cholesterol, use of antihyperten-
sive medication, use of cholesterol-lowering medication, baseline diabetes, hypertension and cardiovascular disease. RAP = bE/bA, where
bE represents the (adjusted) coefficient of the exposure variable, and bA represents the regression coefficient for age. Confidence intervals
were estimated as follows: bE/bA § 1.96 xvar(bE/bA). *Townsend deprivation index: each participant was assigned a numerical score cor-
responding to their postcode (range 6.26  11.00) with higher number representing greater deprivation.
Cancer incidence Cancer death
Comparator RAP (95% CI) RAP (95% CI)
Male sex Female 2.7 (1.76.0) 2.5 (1.56.4)
eGFRcys 6089 ml/min/1.73m2 eGFRcys 90 ml/min/1.73m2 0.6 (2.84.1) 1.7 (1.85.2)
eGFRcys <60 ml/min/1.73m2 eGFRcys 90 ml/min/1.73m2 2.8 (2.58.1) 4.5 (1.310.3)
uACR 3 mg/mmol uACR <3 mg/mmol 1.6 (2.65.8) 2.0 (2.36.3)
Previous smoking Never smoker 2.3 (1.66.1) 3.4 (1.27.9)
Current smoking Never smoker 6.8 (0.814.5) 10.9 (0.522.2)
Deprivation + 5 unit increase in Townsend deprivation index* 0.6 (2.23.4) 1.8 (1.04.6)
Body mass index + 5 kg/m2 increase 0.5 (1.93.0) 0.1 (2.12.3)
Type 2 DM No Type 2 DM 0.9 (3.75.6) 2.9 (2.38.2)
Cardiovascular disease No CVD 0.2 (4.14.4) 1.5 (2.65.5)
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is similar to that observed for previous smoking (RAP 2.3 (1.6  6.1)
years) and greater than observed for type 2 diabetes (RAP 0.9 (3.7 
5.6) years; Table 5). Current smoking is associated with the greatest
RAP (6.8 (0.9  14.5) years). eGFRcys<60 is associated with RAP of
4.5 (1.310.3) years for cancer death, suggesting that a person with
more advanced CKD has a risk of cancer death equivalent to a person
without CKD who is (on average) 4.5 years older. The effect is greater
than that observed for greater deprivation: RAP 1.8 (1.0  4.6) years
per 5-unit increase in deprivation score (equivalent to a transition up
at least one deprivation quintile).
5. Discussion
We have demonstrated that increased risks of cancer incidence
and cancer death may be detectable early in CKD, and are more read-
ily detected using eGFRcys, which is more sensitive and intuitively
linear than eGFRcr or eGFRcr-cys. eGFRcys and uACR are associated
with increased risk of site-specific haematological, renal, respiratory
and abdominal cancers. eGFRcys appears to advance the risk of can-
cer incidence and cancer death to a similar degree as other known
risk factors, such as type 2 diabetes, higher BMI, greater deprivation
and previous smoking.
To our knowledge, this is the first study to compare eGFRcr,
eGFRcys and eGFRcr-cys for cancer risk. In contrast to studies that
assessed the association between eGFRcr[3,5,711,27] or eGFRcr-cys
[4] with cancer incidence and death, we have shown that eGFRcys
6089 ml/min/1.73m2 is associated with small but significant
increases in cancer incidence, and a more pronounced association
with cancer death.
The strong association between CKD and haematological cancers
[10] may be due to shared risk factors including viral infections (hep-
atitis B, C, HIV, Epstein-Barr and cytomegalovirus) and the effects of
immunosuppression [28]. Some haematological malignancies (e.g.,
multiple myeloma) may directly cause kidney failure: declining kid-
ney dysfunction may represent an early manifestation of malignancy.
We conducted sensitivity analyses (excluding participants who
developed renal tract cancers and multiple myeloma, and one-year
landmark analyses) in an attempt to assess and attenuate the impact
of pre-symptomatic cancer on eGFR measures. Our conclusions were
unchanged, but we accept that there remains potential for some of
our findings being linked to reverse causality.
A more consistent association is observed between CKD and can-
cers of the urinary tract [1,3,79,29], which share common risk fac-
tors, such as the metabolic syndrome, smoking, prior nephrectomy,
genetic conditions (such as tuberous sclerosis), occupationalPlease cite this article as: J.S. Lees et al., Kidney function and cancer r
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known to contribute to CKD development [30] and is more likely to
occur in those with CKD. Cell damage induced by AKI has been shown
to promote clonal proliferation of renal progenitors as part of the
healing response, leading to the development of renal cell carcinoma
subtypes including metastatic disease [31]. Strategies to prevent both
AKI and CKD (as a risk factor for AKI) may directly reduce the risk of
renal tract cancers in this population.
Lung cancer has previously been associated with reduced eGFR [3]
and more consistently with albuminuria [35,14]. This effect is
slightly attenuated when taking account of history of smoking [4,14],
suggesting that albuminuria may be a marker of susceptibility to can-
cer or tissue damage associated with smoking. Cancer and albumin-
uria have been associated with inflammatory states [32,33], and
albuminuria may simply be a marker of increased inflammation and
endothelial dysfunction. However, albuminuria remained association
with risk of overall and site-specific haematological, abdominal, renal
and respiratory and more weakly associated with digestive and head
and neck cancers, even after adjustment for C-reactive protein as a
marker of inflammation. Further exploration of the mechanisms
underlying this association are warranted.
CKD is associated with cardiovascular disease: the heightened risk
is detected earlier and more strongly by eGFRcys or eGFRcr-cys com-
pared to eGFRcr [2,16,34]. Mendelian randomisation studies demon-
strate that the association between elevated cystatin C and coronary
artery disease is not causal, but is mediated by eGFR [35]. Cancer, car-
diovascular disease and kidney disease share common risk factors
such as increasing age, smoking, inflammation and the metabolic
syndrome. eGFRcys appears to capture the aggregated metabolic and
inflammatory profile associated with chronic disease in a way that is
clinically relevant and straightforward for clinicians to test and inter-
pret. Given the heightened risks of cardiovascular disease and cancer,
improving knowledge about kidney function may help with risk
stratification and healthcare planning, particularly in a condition that
is largely asymptomatic until late in the disease course.
There are several possible explanations for the excess cancer
death observed in CKD. People with CKD may be diagnosed with can-
cer at a more invasive stage, either through suboptimal symptom rec-
ognition or more aggressive disease. People with CKD are
systematically under-represented in clinical cancer trials [3638]:
the evidence-base for cancer treatment in CKD is less well-estab-
lished, and patients with CKDmay receive cancer treatment regimens
that are less effective or less aggressive. In CKD, side effects (espe-
cially renal side effects including AKI [39]) may be more common,
and patients with CKD may be unable to tolerate the dose or duration
of anti-cancer therapy for effective treatment. Medications used inisk: An analysis using creatinine and cystatin C in a cohort study,
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pies, limiting their effectiveness. Exploration of these issues is war-
ranted in datasets with more granular information on cancer staging
and treatments in participants with CKD.
We acknowledge some limitations to this work. First, kidney func-
tion is estimated based on a single baseline value of creatinine or cys-
tatin C, with no information on kidney disease progression over time.
Second, UK Biobank does not hold data on cancer symptoms, staging
at diagnosis or treatment modalities, so we cannot assess the impact
of CKD markers on treatments and outcomes. Third, cause of death
was ascertained from linkage to death registry records, rather than as
adjudicated endpoints: it is possible that misclassification of the cause
of death could have occurred leading to over- or under-estimation of
the risk associated with eGFR or albuminuria. Fourth, we have not
adjusted for hormonal influences in women, however, CKD is associ-
ated with disruption in hormonal signalling and fertility [40] and eGFR
measures may have captured some of these influences. Further, hor-
mone profiles will not be routinely measured in primary care. Fifth,
there are fewer participants with eGFR <30 ml/min/1.73m2, so we are
unable to comment on the impact of more advanced CKD. Sixth, the
included participants were relatively young (all under 74 years old),
therefore we cannot be confident the same associations would be
observed in more elderly people, in whom cancer and lower eGFR are
more common. Seventh, small representation of non-White ethnic
groups may limit generalisability of the findings. Last, UK Biobank is
not representative of UK population in terms of lifestyles. Cancer inci-
dence in UK Biobank is around 30% lower than in the general popula-
tion [41] and absolute risk may not be generalisable. However, hazard
ratios should still be applicable to the general UK population [41].
There is an excess risk of cancer incidence and cancer death in
CKD that is detected earlier and more readily by eGFRcys than by cur-
rent measures. The heightened risk associated with eGFR<60 is at
least as important as other recognised risk factors such as obesity,
type 2 diabetes, deprivation and previous smoking. The impact of
CKD markers on cancer death in particular is concerning and war-
rants further scrutiny.Funding
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